This article is more than 5 years old. Information may no longer be current.
Six important updates in cervical cancer
Nearly 13,000 women in the United States are diagnosed with cervical cancer every year, according to the National Cervical Cancer Coalition. January is Cervical Health Awareness Month, encouraging people to undergo screening for HPV, the most common cause of cervical cancer.
To help raise awareness, HemOnc Today compiled a list of recent updates in prevention and treatment of cervical cancer:
The U.S. Preventive Services Task Force issued a draft recommendation statement and evidence review supporting cervical cancer screening among women aged 21 to 65 years, formally endorsing the use of HPV primary screening every 5 years for women aged 30 to 65 years. READ MORE.
Alternative options for cervical cancer screening, such as self-sampling HPV tests, could increase screening uptake among transgender men. READ MORE.
The addition of bevacizumab (Avastin, Genentech) to chemotherapy continued to show significant survival benefits among women with advanced cervical cancer. Patients who received the combination therapy lived 3.5 months longer than those assigned chemotherapy alone. READ MORE.
High-dose brachytherapy delivered in four fractions of 7 Gy conferred a higher rate of 5-year tumor control than two fractions of 9 Gy among patients with cervical cancer undergoing external beam radiotherapy. READ MORE.
Neoadjuvant chemotherapy followed by radical surgery did not improve outcomes compared with cisplatin-based concurrent chemoradiation for women with locally advanced squamous carcinoma of the cervix. READ MORE.
Women with HIV on antiretroviral therapy had a lower prevalence of high-risk HPV infection, high-grade cervical lesions and invasive cervical cancer than women who did not receive antiretroviral therapy. READ MORE.